These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 17408075)
1. A pharmacoeconomic comparison of monotherapy with Tegretol, Finlepsin and Trileptal (preliminary data). Balabanov PP; Zahariev ZI Folia Med (Plovdiv); 2006; 48(2):37-43. PubMed ID: 17408075 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic aspects of monotherapy of focal epilepsy]. Mkrtchyan VR; Kaimovsky IL Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(11. Vyp. 2):92-98. PubMed ID: 32207738 [TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952 [TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Muller M; Marson AG; Williamson PR Cochrane Database Syst Rev; 2006 Apr; (2):CD003615. PubMed ID: 16625587 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents]. Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Suppl 1):45-50. PubMed ID: 20559267 [TBL] [Abstract][Full Text] [Related]
6. [The use of the antiepileptic drug trileptal in the clinical practice]. Gromov SA; Eroshina ES; Lipatova LV Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):47-50. PubMed ID: 18577957 [TBL] [Abstract][Full Text] [Related]
7. Spotlight on oxcarbazepine in epilepsy. Bang LM; Goa KL CNS Drugs; 2004; 18(1):57-61. PubMed ID: 14731060 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents]. Belousova ED; Mukhin KIu; Ermolenko NA; Guzeva VI; Tysiachina MD; Mironov MB; Petrukhin AS Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):45-50. PubMed ID: 21322825 [TBL] [Abstract][Full Text] [Related]
9. Oxcarbazepine: a review of its use in children with epilepsy. Bang L; Goa K Paediatr Drugs; 2003; 5(8):557-73. PubMed ID: 12895138 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the factors affecting the quality of life and total costs in epilepsy patients on monotherapy with carbamazepine and valproate. Balabanov PP; Zahariev ZI; Mateva NG Folia Med (Plovdiv); 2008; 50(2):18-23. PubMed ID: 18702221 [TBL] [Abstract][Full Text] [Related]
11. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Garnett WR; Gilbert TD; O'Connor P Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489 [TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL Value Health; 2007; 10(3):173-82. PubMed ID: 17532810 [TBL] [Abstract][Full Text] [Related]
13. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy. Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B; Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062 [TBL] [Abstract][Full Text] [Related]
14. [Comparison of efficacy of trileptal (oxcarbazepine) and carbamazepine in the treatment of temporal epilepsy]. Sokolova LV; Kalinin VV; Zheleznova EV; Zemlianaia AA; Polianskiĭ DA; Basamygin AV Zh Nevrol Psikhiatr Im S S Korsakova; 2008; Suppl 2():63-7. PubMed ID: 19431253 [TBL] [Abstract][Full Text] [Related]
16. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. Maschio M; Dinapoli L; Sperati F; Fabi A; Pace A; Vidiri A; Muti P J Neurooncol; 2012 Feb; 106(3):651-6. PubMed ID: 21847705 [TBL] [Abstract][Full Text] [Related]
17. A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis. Lee WC; Hoffmann MS; Arcona S; D'Souza J; Wang Q; Pashos CL Clin Ther; 2005 Oct; 27(10):1629-38. PubMed ID: 16330300 [TBL] [Abstract][Full Text] [Related]
18. Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial. Maiti R; Mishra BR; Sanyal S; Mohapatra D; Parida S; Mishra A Epilepsy Res; 2017 Dec; 138():5-10. PubMed ID: 29028517 [TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Connock M; Frew E; Evans BW; Bryan S; Cummins C; Fry-Smith A; Li Wan Po A; Sandercock J Health Technol Assess; 2006 Mar; 10(7):iii, ix-118. PubMed ID: 16545206 [TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]